In an article published online this week in Nature Genetics, a University of Colorado Cancer Center team in partnership with universities in China and Denmark reports the first genetic sequencing of urothelial (transitional) carcinoma, the most prevalent type of bladder cancer. Recognizing the genetic mutations that make bladder cancer cells different than their healthy neighbors may allow early genetic screenings for cancer and new therapies targeting cells with these mutations.
